SCHEMBL834524

SCHEMBL834524

COC(=O)c1ccc(OCCc2ccc(Br)cc2)cc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.66
RAB9A P51151 3/20 0.59
CYP4A11 Q02928 2/20 0.53
MAOB P27338 1/20 0.52
NPC1 O15118 2/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
MEN1 O00255 1/20 0.52
KMT2A Q03164 1/20 0.52
PPARD Q03181 2/20 0.52
PPARA Q07869 2/20 0.52
CYP4F2 P78329 1/20 0.51
TDP1 Q9NUW8 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
RXRA P19793 1/20 0.50
RXRB P28702 1/20 0.50
GAA P10253 1/20 0.49
CCR6 P51684 1/20 0.49
HKDC1 Q2TB90 1/20 0.49
LOXL2 Q9Y4K0 1/20 0.49
CA1 P00915 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2653776 0.90 MAPT (0.60) MAPTRAB9ACYP4A11MAOBNPC1
SCHEMBL9038241 0.87 MAPT (0.68) MAPTRAB9ACYP4A11MAOBNPC1
SCHEMBL14967260 0.87 MAPT (0.68) MAPTRAB9ACYP4A11MAOBNPC1
SCHEMBL14966315 0.87 MAPT (0.68) MAPTRAB9ACYP4A11MAOBNPC1
SCHEMBL4364274 0.85 MAPT (0.66) MAPTRAB9ACYP4A11MAOBNPC1
SCHEMBL5392156 0.85 MAPT (0.77) MAPTRAB9ACYP4A11NPC1SMN1; SMN2
SCHEMBL4361298 0.85 MAPT (0.77) MAPTRAB9ANPC1SMN1; SMN2MEN1
SCHEMBL14967130 0.83 MAPT (0.54) MAPTRAB9ACYP4A11NPC1SMN1; SMN2
SCHEMBL14967039 0.83 MAPT (0.62) MAPTRAB9ACYP4A11NPC1SMN1; SMN2
SCHEMBL28756746 0.82 MAPT (0.57) MAPTRAB9ANPC1SMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8497397-B2 Substituted acrylamide derivative and pharmaceutical composition comprising the same DAIICHI SANKYO COMPANY, LIMITED (JP) 2013-07-30 US disclosed
EP-1880720-B1 SUBSTITUTED ACRYLAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME DAIICHI SANKYO CO LTD (JP) 2013-02-13 EP disclosed
US-20120220593-A1 Substituted Acrylamide Derivative and Pharmaceutical Composition Comprising the Same DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-08-30 US disclosed
US-8143446-B2 Substituted acrylamide derivative and pharmaceutical composition comprising the same DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-03-27 US disclosed
US-20090118199-A1 SUBSTITUTED ACRYLAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME DAIICHI SANKYO COMPANY , LIMITED (JP) 2009-05-07 US disclosed
EP-1880720-A1 SUBSTITUTED ACRYLAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME Daiichi Sankyo Company, Limited (JP) 2008-01-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090118199-A1 SUBSTITUTED ACRYLAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME ACR, NAT1, C1S MAPT 2207/4885RAB9A 2854/4885CYP4A11 116/4885
US-20120220593-A1 Substituted Acrylamide Derivative and Pharmaceutical Composition Comprising the Same ACR, NAT1, C1S MAPT 2207/4885RAB9A 2854/4885CYP4A11 116/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.